TY - JOUR
T1 - Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected with Human Immunodeficiency Virus
AU - Massanella, Marta
AU - Puthanakit, Thanyawee
AU - Leyre, Louise
AU - Jupimai, Thidarat
AU - Sawangsinth, Panadda
AU - De Souza, Mark
AU - Suntarattiwong, Piyarat
AU - Kosalarksa, Pope
AU - Borkird, Thitiporn
AU - Kanjanavanit, Suparat
AU - Chokephaibulkit, Kulkanya
AU - Hansudewechakul, Rawiwan
AU - Petdachai, Witaya
AU - Mitchell, Julie L.
AU - Robb, Merlin L.
AU - Trautmann, Lydie
AU - Ananworanich, Jintanat
AU - Chomont, Nicolas
N1 - Funding Information:
Financial support. This work was supported by the NIH (award number R01 AI114236); the Canadian Institutes of Health Research (grant number 364408); and the Réseau SIDA et maladies infectieuses du Fonds de Recherche du Quebec–Santé (FRQS). M. M. is supported by a Beatriu de Pinós (BP) Postdoctoral Fellowship from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya. N. C. is supported by a Research Scholar Career Award of the Quebec Health Research Fund (FRQS, number 253292). M. R. is supported by the NIH (grant number R01 HD 080435-01).
Funding Information:
Potential conflicts of interest. J. A. has received honorarium from Merck, ViiV Healthcare, Gilead, AbbVie, and Roche for participating in advisory meetings. P. S. reports a research grant from the HIV-NAT Research Collaboration. N. C. reports grants from EMD Serono and Gilead, outside the submitted work. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Publisher Copyright:
© 2020 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Background: Early antiretroviral therapy (ART) restricts the size of the human immunodeficiency virus (HIV) reservoir in infants. However, whether antiretroviral (ARV) prophylaxis given to exposed vertically infected children exerts similar effects remains unknown. Methods: We measured total and integrated HIV DNA, as well as the frequency of CD4 T cells producing multiply spliced RNA (msRNA) after stimulation (inducible reservoir) in vertically infected Thai infants. Eighty-five infants were followed longitudinally for up to 3 years. We compared the size of the reservoir in children who received continuous ARV prophylaxis since birth vs those who never received or discontinued prophylaxis before initiating ART. We used samples from a cross-sectional cohort of 37 Thai children who had initiated ART within 6 months of life to validate our findings. Results: Before ART, levels of HIV DNA and the frequencies of cells producing msRNA were significantly lower in infants who received continuous ARV prophylaxis since birth compared to those in whom ARV prophylaxis was discontinued or never initiated (P <. 020 and P <. 001, respectively). Upon ART initiation, total and integrated HIV DNA levels decayed significantly in both groups (P <. 01 in all cases). Interestingly, the initial differences in the frequencies of infected cells persisted during 3 years on ART. The beneficial effect of prophylaxis on the size of the HIV reservoir was confirmed in the cross-sectional study. Importantly, no differences were observed between children who discontinued prophylactic ARVs before starting ART and those who delayed ART initiation without receiving prior prophylaxis. Conclusions: Neonatal ARV prophylaxis with direct transition to ART durably limits the size of the HIV reservoir.
AB - Background: Early antiretroviral therapy (ART) restricts the size of the human immunodeficiency virus (HIV) reservoir in infants. However, whether antiretroviral (ARV) prophylaxis given to exposed vertically infected children exerts similar effects remains unknown. Methods: We measured total and integrated HIV DNA, as well as the frequency of CD4 T cells producing multiply spliced RNA (msRNA) after stimulation (inducible reservoir) in vertically infected Thai infants. Eighty-five infants were followed longitudinally for up to 3 years. We compared the size of the reservoir in children who received continuous ARV prophylaxis since birth vs those who never received or discontinued prophylaxis before initiating ART. We used samples from a cross-sectional cohort of 37 Thai children who had initiated ART within 6 months of life to validate our findings. Results: Before ART, levels of HIV DNA and the frequencies of cells producing msRNA were significantly lower in infants who received continuous ARV prophylaxis since birth compared to those in whom ARV prophylaxis was discontinued or never initiated (P <. 020 and P <. 001, respectively). Upon ART initiation, total and integrated HIV DNA levels decayed significantly in both groups (P <. 01 in all cases). Interestingly, the initial differences in the frequencies of infected cells persisted during 3 years on ART. The beneficial effect of prophylaxis on the size of the HIV reservoir was confirmed in the cross-sectional study. Importantly, no differences were observed between children who discontinued prophylactic ARVs before starting ART and those who delayed ART initiation without receiving prior prophylaxis. Conclusions: Neonatal ARV prophylaxis with direct transition to ART durably limits the size of the HIV reservoir.
KW - Early antiretroviral therapy
KW - HIV reservoir
KW - Paediatric
KW - Prophylaxis
KW - Vertical infection
UR - http://www.scopus.com/inward/record.url?scp=85109387587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109387587&partnerID=8YFLogxK
U2 - 10.1093/cid/ciaa718
DO - 10.1093/cid/ciaa718
M3 - Article
C2 - 32504081
AN - SCOPUS:85109387587
SN - 1058-4838
VL - 73
SP - 427
EP - 438
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -